Annemie Deiteren
Head of Early Clinical & Experimental Therapeutics Sanofi
Board-certified MD PhD & clinical pharmacologist with 10+ years of experience in R&D, both in academia and industry. As group leader for the Early Clinical and Experimental Therapeutics team, my expertise is in building the early development strategy for compounds in the immunology space with a focus an human target validation, early patient data and robust Go/No Go decision making. This includes the design and medical and scientific oversight of First-in-Man, Proof-of-Mechanism and Proof-of-Concept studies with end-to-end thinking while ensuring strategic alignment with therapeutic areas in research and development and addressing dynamic portfolio needs. Recognized for my collaborative leadership style and strategic vision, I empower high-performing teams to deliver innovative development strategies. Passionate about advancing science to improve patient outcomes and shape the future of medicine
Seminars
- Validating inflammatory pathways in vivo using inducible skin challenge models, enabling direct proof-of-mechanism in healthy participants where baseline disease activity is absent, building early confidence that targets are biologically active before committing to patient trials
- Benchmarking multi-pathway modulation against approved single-target therapies to allow mechanistic differentiation and strengthen scientific rationale and prioritisation
- Leveraging phase 0–1 experimental therapeutics data to engage regulators and investigators, translating mechanistic evidence into credible narratives for Phase II readiness, reducing downstream development risk and accelerating progression into patient populations such as HS
